Sernova (TSE:SVA)
TSX:SVA
Top Page
Sernova
(TSX:SVA)
Select Model
Select Model
Rating:47Neutral
Price Target:
C$0.17
▲(11.33% Upside)
Action:ReiteratedDate:03/16/26
The score is held down primarily by very weak fundamentals (pre-revenue, persistent losses and cash burn, and elevated balance-sheet risk with negative equity and higher debt). Technicals are a partial offset with improving momentum versus key moving averages, but valuation remains unattractive due to ongoing losses and no dividend support.
Positive Factors
Proprietary implantable platform
Sernova’s Cell Pouch System is a platform technology targeting durable cell replacement for chronic disease (notably diabetes). As a platform, successful clinical validation could create a sustainable competitive moat and multiple upstream partnership or licensing paths beyond a single product.
Negative Factors
Pre-revenue business model
Sernova remains pre-revenue with no commercial product sales, meaning its long-term viability depends on successful clinical outcomes and external financing. Without recurring revenues, the company faces ongoing dilution risk and limited internal cash generation to fund development.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary implantable platform
Sernova’s Cell Pouch System is a platform technology targeting durable cell replacement for chronic disease (notably diabetes). As a platform, successful clinical validation could create a sustainable competitive moat and multiple upstream partnership or licensing paths beyond a single product.
Read all positive factors
Sernova (SVA) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$52.16M
Dividend YieldN/A
Average Volume (3M)125.66K
Price to Earnings (P/E)―
Beta (1Y)-0.35
Revenue GrowthN/A
EPS Growth54.38%
CountryCA
Employees17
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.01
Shares Outstanding347,726,350
10 Day Avg. Volume126,270
30 Day Avg. Volume125,661
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)-1.96
Price to Sales (P/S)0.00
P/FCF Ratio-4.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.03
Revenue Forecast (FY)C$300.50K
Sernova Business Overview & Revenue Model
Company Description
Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associate...
How the Company Makes Money
Sernova is a clinical-stage biotechnology company and does not have a clearly disclosed, consistent commercial product revenue stream available from public information in this prompt. As a result, detailed, confirmed information on a recurring rev...
Sernova Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
8
Very Negative
Cash Flow
18
Very Negative
| Breakdown | TTM | Oct 2025 | Oct 2024 | Oct 2023 | Oct 2022 | Oct 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -251.70K | -342.59K | 0.00 | -445.55K | -440.00K | -267.20K |
| EBITDA | -11.38M | -14.74M | -31.25M | -40.19M | -24.54M | -6.60M |
| Net Income | -12.38M | -15.74M | -32.19M | -39.00M | -24.54M | -7.02M |
Balance Sheet | ||||||
| Total Assets | 1.01M | 764.23K | 7.53M | 22.11M | 52.48M | 29.82M |
| Cash, Cash Equivalents and Short-Term Investments | 576.22K | 265.00K | 6.01M | 19.81M | 49.78M | 27.87M |
| Total Debt | 17.55M | 17.28M | 569.94K | 136.12K | 275.98K | 393.35K |
| Total Liabilities | 26.61M | 25.84M | 20.48M | 9.59M | 4.88M | 1.75M |
| Stockholders Equity | -25.60M | -25.08M | -12.96M | 12.51M | 47.61M | 28.07M |
Cash Flow | ||||||
| Free Cash Flow | -7.13M | -10.91M | -18.90M | -30.44M | -14.75M | -6.86M |
| Operating Cash Flow | -7.13M | -10.91M | -18.90M | -30.34M | -14.42M | -6.84M |
| Investing Cash Flow | 24.96K | 24.96K | 11.12M | 34.78M | -46.34M | -228.78K |
| Financing Cash Flow | 6.47M | 5.14M | 5.07M | 503.46K | 36.66M | 31.00M |
Sernova Technical Analysis
Negative
0.15
Price Trends
0.15
Negative
0.15
Positive
0.16
Negative
Market Momentum
<0.01
Positive
46.12
Neutral
27.38
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:SVA, the sentiment is Negative. The current price of 0.15 is below the 20-day moving average (MA) of 0.16, below the 50-day MA of 0.15, and below the 200-day MA of 0.16, indicating a bearish trend. The MACD of <0.01 indicates Positive momentum. The RSI at 46.12 is Neutral, neither overbought nor oversold. The STOCH value of 27.38 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:SVA.
Sernova Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | C$50.54M | 95.68 | 3.31% | ― | 5.29% | -29.02% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | C$52.16M | -5.76 | ― | ― | ― | 54.38% | |
45 Neutral | C$31.17M | -6.85 | -8.01% | ― | -26.81% | -161.24% | |
45 Neutral | C$29.83M | -6.55 | ― | ― | ― | 72.92% | |
42 Neutral | C$44.21M | -17.16 | ― | ― | -41.70% | -35.42% |
* Healthcare Sector Average
TSE:SVA
Sernova
0.15
-0.02
-11.76%
TSE:COV
Covalon Technologies
1.83
-0.34
-15.67%
TSE:MBX
Microbix Biosystms
0.23
-0.18
-45.12%
TSE:MIR
Medmira
0.06
-0.02
-25.88%
TSE:NRX
NurExone Biologic
0.65
0.01
1.56%
TSE:DTC
Defence Therapeutics
0.52
-0.38
-42.22%
Sernova Corporate Events
Business Operations and StrategyPrivate Placements and FinancingShareholder Meetings
Sernova Bolsters Balance Sheet With $7.1 Million Financing and Debt Retirement Plan
Positive
Mar 4, 2026
Sernova Biotherapeutics has announced a series of financing transactions totaling $7.1 million, including a non-brokered equity private placement, a convertible debenture from an insider, and a larger insider-led equity financing that is subject t...
Business Operations and StrategyPrivate Placements and Financing
Sernova Amends Warrants to Extend Terms and Cut Exercise Prices for Investors
Positive
Feb 23, 2026
Sernova Biotherapeutics plans to amend terms on a large portion of its outstanding warrants, subject to TSX approval, in a move that adjusts both duration and pricing for non-insider holders. The company will extend the expiry of 19,977,050 warran...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.